title: Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain.
abstract: Rotavirus is not included in the Spanish mass infant vaccination schedule but has also not been economically evaluated for its inclusion. We analysed cost-utility of the universal infant rotavirus vaccination using RotaTeq® versus no vaccination in Spain. We also carried out a budget impact analysis and determined the effect on results of different variables introduced in the model. A deterministic Markov model was built considering loss of quality of life for children and their parents, and introducing direct and indirect costs updated to 2011. The introduction of the vaccination using RotaTeq® as a universal infant vaccination would increase the annual health care budget in 10.43 million euro and would result in a gain of an additional Quality Adjusted Life Year at a cost of 280,338€ from the healthcare system perspective and 210,167€ from the societal perspective. The model was stable to variable modifications. To sum up, according to our model and estimates, the introduction of a universal infant rotavirus vaccination with RotaTeq® in Spain would cause a large impact on the health care budget and would not be efficient unless significant variations in vaccine price, vaccine efficacy and/or utilities took place.
authors.affiliation: Spanish Health Technology Assessment Agency (AETS-Agencia de Evaluación de Tecnologías Sanitarias), Institute for Health "Carlos III", 5 Monforte de Lemos, Madrid 28029, Spain; REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas-Spanish Health Services Research on Cronic Patients Network), Spain. Electronic address: imaz@isciii.es.
authors.forename: Iñaki
authors.initials: I
authors.lastname: Imaz
authors.affiliation: Spanish Health Technology Assessment Agency (AETS-Agencia de Evaluación de Tecnologías Sanitarias), Institute for Health "Carlos III", 5 Monforte de Lemos, Madrid 28029, Spain.
authors.forename: Beltrán
authors.initials: B
authors.lastname: Rubio
authors.affiliation: Preventive Medicine Department, "Ramón y Cajal" Universitary Hospital, Ctra. de Colmenar Viejo km. 9,100, Madrid 28034, Spain. Electronic address: anamariacornejo@hotmail.es.
authors.forename: Ana M
authors.initials: AM
authors.lastname: Cornejo
authors.affiliation: Spanish Health Technology Assessment Agency (AETS-Agencia de Evaluación de Tecnologías Sanitarias), Institute for Health "Carlos III", 5 Monforte de Lemos, Madrid 28029, Spain; REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas-Spanish Health Services Research on Cronic Patients Network), Spain. Electronic address: jgonza@isciii.es.
authors.forename: Jesús
authors.initials: J
authors.lastname: González-Enríquez
mesh_terms: D002017:Budgets; D002675:Child, Preschool; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004059:Diffusion of Innovation; D005260:Female; D005759:Gastroenteritis / Q000453:epidemiology / Q000276:immunology*; D006297:Health Services Accessibility / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D008390:Markov Chains; D032541:Mass Vaccination / Q000191:economics* / Q000379:methods; D009026:Mortality / Q000639:trends; D009313:National Health Programs; D019057:Quality-Adjusted Life Years; D012401:Rotavirus / Q000302:isolation & purification; D012400:Rotavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology; D013030:Spain / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000191:economics / Q000276:immunology; D016903:Drug Monitoring
chemical_list: C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated
keywords: Biomedical; Cost–benefit analysis; Mass vaccination; Medical economics; Rotavirus; Technology assessment